Clearmind Medicine Inc. (CMND) intrinsic value & 10-year financials
Clearmind Medicine Inc. (CMND) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 2556.6%
- Free cash flow (FY2025)
- —
CMND 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$3.9M | -$30.35 | — | — | -179.4% |
| FY2024 | — | -$5.3M | -$1.69 | — | — | -256.9% |
| FY2023 | — | -$8.6M | -$2.84 | — | — | 14071.8% |
| FY2022 | — | -$6.9M | -$10.61 | -$3.7M | — | -707.5% |
| FY2021 | — | -$2.7M | -$5.88 | -$2.1M | — | -145.3% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Clearmind Medicine Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Clearmind Medicine Inc. 10-year average ROIC is N/A; capital efficiency cannot be assessed from the available history.
Over the decade, Clearmind Medicine Inc. shows that management has aggressively returned capital to shareholders by retiring 98.4% of outstanding shares.
Benjamin Graham lens
Clearmind Medicine Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.